pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2020-30-6-813-821pulmo-2217Research ArticleОБЗОРЫREVIEWПервая тройная фиксированная комбинация для пациентов с хронической обструктивной болезнью легких: место в терапии (обзор научных данных)First triple therapy in one inhaler for COPD patients: treatment approach (scientific data overview)https://orcid.org/0000-0002-5999-2150АвдеевС. Н.AvdeevS. N.

Авдеев Сергей Николаевич - доктор медицинских наук, профессор, член-корр. Российской академии наук, заведующий кафедрой пульмонологии Первый МГМУ им.И.М.Сеченова (Сеченовский Университет), руководитель клинического отдела НИИП.

119991, Москва, ул. Трубецкая, 8, стр. 2; 115682, Москва, Ореховый бульвар, 28; тел.: (495) 708-35-76

Sergey N. Avdeev - Doctor ofMedicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Se-chenov First Moscow SMU, (Sechenov University); Head of Clinical Division, Federal PRI, Federal Medical and Biological Agency of Russia.

Ul. Trubetskaya 8, build. 2, Moscow, 119991; Orekhovyy bul'var 28, Moscow, 115682; tel.: (495) 708-35-76

serg_avdeev@list.ruhttps://orcid.org/0000-0002-4044-674XАйсановЗ. Р.AisanovZ. R.

Айсанов Заурбек Рамазанович — доктор медицинских наук, профессор кафедры пульмонологии.

Zaurbek R. Aisanov, Doctor of Medicine, Professor, Department of Pulmonology.

Ul. Ostrovityanova 1, Moscow, 117997; tel.: (495) 965-34-66

aisanov@mail.ruhttps://orcid.org/0000-0002-8574-6869ЕмельяновА. В.EmelyanovA. V.

Емельянов Александр Викторович — доктор медицинских наук, профессор, заведующий кафедрой пульмонологии.

191015, Санкт-Петербург, ул. Кирочная, 41; тел.: (901) 970-71-88

Aleksandr V. Emel'yanov - Doctor of Medicine, Professor, Head of Department of Pulmonology.

Ul. Kirochnaya 41, St. Petersburg, 191015, Russia; tel.: (812) 970-71-88

emelav@inbox.ruФедеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М.Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Федеральное государственное бюджетное учреждение Научно-исследовательский институт пульмонологии Федерального медико-биологического агентстваРоссияI.M.Sechenov First Moscow State Medical University (Sechenov University), Healthcare Ministry of Russia; Federal Pulmonology Research Institute, Federal Medical and Biological Agency of RussiaRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Министерства здравоохранения Российской ФедерацииРоссияN.J. Pirogov Federal Russian National Research Medical University, Healthcare Ministry of RussiaRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет имени И.И.Мечникова» Министерства здравоохранения Российской ФедерацииРоссияL.L. Mechnikov State North-West Medical University, Healthcare Ministry of RussiaRussian Federation202023122020306813821Copyright © Авдеев С.Н., Айсанов З.Р., Емельянов А.В., 20202020Авдеев С.Н., Айсанов З.Р., Емельянов А.В.Avdeev S.N., Aisanov Z.R., Emelyanov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2217

Хроническая обструктивная болезнь легких (ХОБЛ) является одной из ведущих причин нетрудоспособности и смерти. В работе обсуждаются возможности использования фиксированных тройных комбинаций для базисной терапии ХОБЛ на примере первой зарегистрированной в Российской Федерации тройной комбинации Треледжи Эллипта — классы препаратов и их механизмы действия, клиническая эффективность, а также их влияние не только на риск обострений, функциональные пациент-ориентированные исходы, показатели безопасности, но и снижение риска летального исхода. Рассматриваются подходы к назначению тройных комбинаций для базисной терапии ХОБЛ, рекомендуемые различными национальными и глобальными руководствами и соглашениями.

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of disability and mortality. The paper discusses the role of single inhaler triple therapy in COPD maintenance treatment. Trelegy Ellipta - the first fixed triple combination registered in Russia - is taken as an example. Below we deliberate on classes of components and their mechanism of action, clinical effectiveness, influence on exacerbations' risk, functional and patient-reported outcomes, safety, and mortality reduction. We also discuss the approaches for triple therapy administration to COPD patients recommended by a row of national and global guidelines.

хроническая обструктивная болезнь легких (ХОБЛ)поддерживающая терапия ХОБЛтройная терапияингаляционные глюкокортикостероидытройные комбинацииобострения ХОБЛТреледжи Эллиптаchronic obstructive pulmonary disease (COPD)COPD maintenance treatmenttriple therapyinhaled corticosteroidtriple combinationsCOPD exacerbationsTrelegy ElliptaСтатья подготовлена при поддержке компании Акционерное общество «ГлаксоСмитКляйн Трейдинг» в соответствии с действующим законодательством Российской Федерации и принципами добросовестной практики научных публикаций (Good Publication Practice)This publication is supported by GlaxoSmithKline Trading Joint Stock Company, according to the current legislation of Russian Federation and Good Publication Practice standardsReferencesGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). Available at: https://goldcopd.org/wp-con-tent/uploаds/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf [Accessed: May 11, 2020].Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). Available at: https://goldcopd.org/wp-con-tent/uploаds/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf [Accessed: May 11, 2020].Antoniu S.A., Carone M. Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. Expert Rev. Pharmacoecon. Outcomes Res. 2013; 13 (2): 187-189. DOI: 10.1586/erp.13.9.Antoniu S.A., Carone M. Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. Expert Rev. Pharmacoecon. Outcomes Res. 2013; 13 (2): 187-189. DOI: 10.1586/erp.13.9.Российское респираторное общество. Клинические рекомендации. Хроническая обструктивная болезнь легких. 2018. Доступно на: http://spulmo.ru/obrazovatel-nye-resursy/federalnye-klinicheskie-rekomendatsii/ [Дата обращения: 21.10.19].Russian Respiratory Society. Clinical guidelines. [Chronic obstructive pulmonary disease]. Available at: http://spulmo.ru/obrazovatelnye-res-ursy/federalnye-klinicheskie-rekomendatsii/ [Accessed: December 21, 2019] (in Russian).Nici L., Mammen M.J., Charbek E. et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am. J. Respir. Crit. Care Med. 2020; 201 (9): e56-69. DOI: 10.1164/rccm.202003-0625ST.Nici L., Mammen M.J., Charbek E. et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am. J. Respir. Crit. Care Med. 2020; 201 (9): e56-69. DOI: 10.1164/rccm.202003-0625ST.Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2 (4): 297-304; discussion 311-312. DOI: 10.1513/pats.200504-043SR.Belmonte K.E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2 (4): 297-304; discussion 311-312. DOI: 10.1513/pats.200504-043SR.Toy E.L., Beaulieu N.U., McHale J.M. et al. Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs. Respir. Med. 2011; 105 (3): 435-441. DOI: 10.1016/j.rmed.2010.09.006.Toy E.L., Beaulieu N.U., McHale J.M. et al. Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs. Respir. Med. 2011; 105 (3): 435-441. DOI: 10.1016/j.rmed.2010.09.006.Babu K.S., Morjaria J.B. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther. Adv. Chronic. Dis. 2017; 8 (4-5): 81-91. DOI: 10.1177/2040622317700822.Babu K.S., Morjaria J.B. Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther. Adv. Chronic. Dis. 2017; 8 (4-5): 81-91. DOI: 10.1177/2040622317700822.Salmon M., Luttmann M.A., Foley J.J. et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J. Pharmacol. Exp. Ther. 2013; 345 (2): 260-270. DOI: 10.1124/jpet.112.202051.Salmon M., Luttmann M.A., Foley J.J. et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J. Pharmacol. Exp. Ther. 2013; 345 (2): 260-270. DOI: 10.1124/jpet.112.202051.Trivedi R., Richard N., Mehta R., Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur. Respir. J. 2014; 43 (1): 72-81. DOI: 10.1183/09031936.00033213.Trivedi R., Richard N., Mehta R., Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur. Respir. J. 2014; 43 (1): 72-81. DOI: 10.1183/09031936.00033213.Pleasants R.A., Wang T., Gao J. et al. Inhaled umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016; 76 (3): 343-361. DOI: 10.1007/s40265-015-0532-5.Pleasants R.A., Wang T., Gao J. et al. Inhaled umeclidinium in COPD patients: a review and meta-analysis. Drugs. 2016; 76 (3): 343-361. DOI: 10.1007/s40265-015-0532-5.Feldman G., Maltais F., Khindri S. et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 719-730. DOI: 10.2147/COPD.S102494.Feldman G., Maltais F., Khindri S. et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 719-730. DOI: 10.2147/COPD.S102494.Malerba M., Nardin M., Santini G. et al. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. Ther. Adv. Respir. Dis. 2018; 12: 175346661876 0779. DOI: 10.1177/1753466618760779.Malerba M., Nardin M., Santini G. et al. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. Ther. Adv. Respir. Dis. 2018; 12: 175346661876 0779. DOI: 10.1177/1753466618760779.Hanania N.A., Feldman G., Zachgo W et al. The efficacy and safety of the novel long-acting в2 agonist vilanterol in patients with COPD: a randomised placebo-controlled trial. Chest. 2012; 142 (1): 119-127. DOI: 10.1378/chest.11-2231.Hanania N.A., Feldman G., Zachgo W et al. The efficacy and safety of the novel long-acting в2 agonist vilanterol in patients with COPD: a randomised placebo-controlled trial. Chest. 2012; 142 (1): 119-127. DOI: 10.1378/chest.11-2231.Jiang Z., Zhu L. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2016; 37: 1-8. DOI: 10.1016/j.pupt.2016.01.002.Jiang Z., Zhu L. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2016; 37: 1-8. DOI: 10.1016/j.pupt.2016.01.002.Pascoe S., Locantore N., Dransfield M.T. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3 (6): 435-442. DOI: 10.1016/S2213-2600(15)00106-X.Pascoe S., Locantore N., Dransfield M.T. et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir. Med. 2015; 3 (6): 435-442. DOI: 10.1016/S2213-2600(15)00106-X.Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting 0-2 agonist efficacy in COPD. Thorax. 2016; 71 (2):118-125. DOI: 10.1136/tho-raxjnl-2015-207021.Pavord I.D., Lettis S., Locantore N. et al. Blood eosinophils and inhaled corticosteroid/long-acting 0-2 agonist efficacy in COPD. Thorax. 2016; 71 (2):118-125. DOI: 10.1136/tho-raxjnl-2015-207021.Daley-Yates P.T. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br. J. Clin. Pharmacol. 2015; 80 (3): 372-380. DOI: 10.1111/bcp.12637.Daley-Yates P.T. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br. J. Clin. Pharmacol. 2015; 80 (3): 372-380. DOI: 10.1111/bcp.12637.Rossios C., To Y., To M. et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur. J. Pharmacol. 2011; 670 (1): 244-251. DOI: 10.1016/j.ejphar.2011.08.022.Rossios C., To Y., To M. et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur. J. Pharmacol. 2011; 670 (1): 244-251. DOI: 10.1016/j.ejphar.2011.08.022.van Boven J.F.M., Chavannes N.H., van der Molen T. et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir. Med. 2014; 108 (1): 103-113. DOI: 10.1016/j.rmed.2013.08.044.van Boven J.F.M., Chavannes N.H., van der Molen T. et al. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir. Med. 2014; 108 (1): 103-113. DOI: 10.1016/j.rmed.2013.08.044.Siler T.M., Kerwin E., Sousa A.R. et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomised studies. Respir. Med. 2015; 109 (9): 1155-1163. DOI: 10.1016/j.rmed.2015.06.006.Siler T.M., Kerwin E., Sousa A.R. et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: results of two randomised studies. Respir. Med. 2015; 109 (9): 1155-1163. DOI: 10.1016/j.rmed.2015.06.006.Lipson D.A., Barnacle H., Birk R. et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 196 (4): 438-446. DOI: 10.1164/rccm.201703-0449OC.Lipson D.A., Barnacle H., Birk R. et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2017; 196 (4): 438-446. DOI: 10.1164/rccm.201703-0449OC.Pascoe S.J., Lipson D.A., Locantore N. et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur. Respir. J. 2016; 48 (2): 320-330. DOI: 10.1183/13993003.02165-2015.Pascoe S.J., Lipson D.A., Locantore N. et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur. Respir. J. 2016; 48 (2): 320-330. DOI: 10.1183/13993003.02165-2015.Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671-1680. DOI: 10.1056/NEJMoa1713901.Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671-1680. DOI: 10.1056/NEJMoa1713901.Lipson D.A., Crim C., Criner G.J. et al. Reduction in allcause mortality with fluticasone furoate/umeclidinium/ vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2020; 201 (12): 1508-1516. DOI: 10.1164/rccm.201911-2207OC.Lipson D.A., Crim C., Criner G.J. et al. Reduction in allcause mortality with fluticasone furoate/umeclidinium/ vilanterol in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2020; 201 (12): 1508-1516. DOI: 10.1164/rccm.201911-2207OC.

The authors declare that there are no conflicts of interest present.